Bacterial infection-driven lymphomagenesis.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
27
7
2022
medline:
12
8
2022
entrez:
26
7
2022
Statut:
ppublish
Résumé
The first convincing evidence for a causal relationship between bacterial infection and lymphomagenesis came from the link between gastric lymphoma and chronic Helicobacter pylori gastritis. This review will summarize the current epidemiological, clinical, and biological evidence of a causative role of bacteria in the development of malignant lymphomas, particularly, the extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type. Other microorganisms have been associated with specific extranodal lymphoma sites with variable and not always definitive, evidence, including Chlamydia psittaci , Borrelia burgdorferi , Campylobacter jejuni and, most recently, Coxiella Burnetii . According to most plausible models, lymphoma growth is a consequence of continuous antigenic stimulation induced by chronic infection. However, some evidence of a direct oncogenic role of H. pylori has been provided, too. Lymphomas are not the result of a single cause but multifactorial diseases, influenced by a variety of genetic and environmental elements. Hence, ascertaining the specific contribution of bacterial infections is not always easy. Nevertheless, the eradication of the associated chronic infection may result in sustained lymphoma regression. Moreover, the association between infections and lymphoma may offer opportunities for reducing lymphoma incidence by preventing the predisposing infections or treating them early.
Identifiants
pubmed: 35880463
doi: 10.1097/CCO.0000000000000886
pii: 00001622-202209000-00007
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
454-463Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020; 8:e180–e190.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249.
Hatano Y, Ideta T, Hirata A, et al. Virus-driven carcinogenesis. Cancers (Basel) 2021; 13:2625.
Pollard J. Bacteria, inflammation and cancer. Nat Rev Immunol 2015; 15:528.
Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 2016; 34:4270–4276.
Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 2018; 18:309–324.
Mortezaee K, Majidpoor J. Key promoters of tumor hallmarks. Int J Clin Oncol 2022; 27:45–58.
Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer. Semin Immunol 2018; 40:74–82.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539–545.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436–444.
Galdiero MR, Marone G, Mantovani A. Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol 2018; 10:a028662.
Deyell M, Garris CS, Laughney AM. Cancer metastasis as a nonhealing wound. Br J Cancer 2021; 124:1491–1502.
van Elsland D, Neefjes J. Bacterial infections and cancer. EMBO Rep 2018; 19:e46632.
Lax AJ. Opinion: bacterial toxins and cancer--a case to answer? Nat Rev Microbiol 2005; 3:343–349.
Strickertsson JAB, Desler C, Rasmussen LJ. Bacterial infection increases risk of carcinogenesis by targeting mitochondria. Semin Cancer Biol 2017; 47:95–100.
De Spiegeleer B, Verbeke F, D’Hondt M, et al. The quorum sensing peptides PhrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro. PLoS One 2015; 10:e0119471.
Wynendaele E, Verbeke F, D’Hondt M, et al. Crosstalk between the microbiome and cancer cells by quorum sensing peptides. Peptides 2015; 64:40–48.
Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer. Science 2021; 371:eabc4552.
Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127–1131.
Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114:1169–1179.
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.
Doglioni C, Wotherspoon AC, Moschini A, et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992; 339:834–835.
Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330:1267–1271.
Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med 2022; 386:568–581.
Ferreri AJ, Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med 2009; 265:421–438.
Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. Blood 2016; 127:2082–2092.
Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 2013; 13:118–132.
Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2:323–335.
Cerhan JR, Habermann TM. Epidemiology of marginal zone lymphoma. Ann Lymphoma 2021; 5:1.
Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96:586–594.
Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350:239–248.
Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000; 31:263–268.
Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000; 24:1279–1285.
Cerroni L, Zöchling N, Pütz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997; 24:457–461.
Sammassimo S, Pruneri G, Andreola G, et al. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol 2016; 34:177–183.
Adam P, Czapiewski P, Colak S, et al. Prevalence of Achromobacter xylosoxidans in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. Br J Haematol 2014; 164:804–810.
Bracci PM, Benavente Y, Turner JJ, et al. Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 2014:52–65.
Vannata B, Arcaini L, Zucca E. Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know? Ther Adv Hematol 2016; 7:94–107.
Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:17–29.
Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015; 92:11–31.
Melenotte C, Mezouar S, Mège JL, et al. Bacterial infection and non-Hodgkin's lymphoma. Crit Rev Microbiol 2020; 46:270–287.
Sassone M, Ponzoni M, Ferreri AJM. Antibiotic treatment for bacteria-associated extranodal marginal zone lymphoma. Ann Lymphoma 2021; 5:4.
Zullo A, Hassan C, Ridola L, et al. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol 2013; 47:824–827.
Kuo SH, Yeh KH, Wu MS, et al. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Sci Rep 2017; 7:14333.
Raderer M, Wöhrer S, Kiesewetter B, et al. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up. Ann Hematol 2015; 94:969–973.
Kuo SH, Yeh KH, Lin CW, et al. Current status of the spectrum and therapeutics of helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma. Cancers (Basel) 2022; 14:1005.
Stolte M, Bayerdörffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002; 50:Iii19–Iii24.
Parsonnet J. Gastric adenocarcinoma and Helicobacter pylori infection. West J Med 1994; 161:60.
Zullo A, Hassan C, Andriani A, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol 2009; 104:1932–1937.
Grünberger B, Wöhrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006; 24:1370–1375.
Ponzoni M, Ferreri AJ. Bacteria associated with marginal zone lymphomas. Best Pract Res Clin Haematol 2017; 30:32–40.
Lin WC, Tsai HF, Kuo SH, et al. Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res 2010; 70:5740–5748.
Kuo S-H, Wu M-S, Yeh K-H, et al. Novel insights of lymphomagenesis of helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma. Cancers 2019; 11:547.
Ferreri AJ, Govi S, Raderer M, et al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood 2012; 120:3858–3860.
Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood 2012; 119:4838- L 4844.
Kuo SH, Yeh KH, Chen LT, et al. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J 2014; 4:e220.
Kuo SH, Cheng AL. Helicobacter pylori and mucosa-associated lymphoid tissue: what's new. Hematology Am Soc Hematol Educ Program 2013; 2013:109–117.
Cheng Y, Xiao Y, Zhou R, et al. Prognostic significance of helicobacter pylori-infection in gastric diffuse large B-cell lymphoma. BMC Cancer 2019; 19:842.
Deng Y, Su W, Zhu J, et al. Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma. J Immunother Cancer 2021; 9:e002947.
Perrone S, D’Elia GM, Annechini G, Pulsoni A. Infectious aetiology of marginal zone lymphoma and role of anti-infective therapy. Mediterr J Hematol Infect Dis 2016; 8:e2016006.
Ponzoni M, Ferreri AJ, Guidoboni M, et al. Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods. Clin Cancer Res 2008; 14:5794–5800.
Ferreri AJ, Dolcetti R, Dognini GP, et al. Int J Cancer 2008; 123:1089–1093.
Ferreri AJ, Dolcetti R, Magnino S, et al. A woman and her canary: a tale of chlamydiae and lymphomas. J Natl Cancer Inst 2007; 99:1418–1419.
Ferreri AJ, Dolcetti R, Magnino S, et al. Chlamydial infection: the link with ocular adnexal lymphomas. Nat Rev Clin Oncol 2009; 6:658–669.
Miyairi I, Byrne GI. Chlamydia and programmed cell death. Curr Opin Microbiol 2006; 9:102–108.
Byrne GI, Ojcius DM. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat Rev Microbiol 2004; 2:802–808.
Dagklis A, Ponzoni M, Govi S, et al. Immunoglobulin gene repertoire in ocular adnexal lymphomas: hints on the nature of the antigenic stimulation. Leukemia 2012; 26:814–821.
Decaudin D, Dolcetti R, de Cremoux P, et al. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations? Anticancer Drugs 2008; 19:761–765.
Ferreri AJ, Dolcetti R, Du MQ, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol 2008; 19:835–846.
Carugi A, Onnis A, Antonicelli G, et al. Geographic variation and environmental conditions as cofactors in Chlamydia psittaci association with ocular adnexal lymphomas: a comparison between Italian and African samples. Hematol Oncol 2010; 28:20–26.
Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012; 30:2988–2994.
Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006; 98:1375–1382.
Han JJ, Kim TM, Jeon YK, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Ann Hematol 2015; 94:575–581.
de la Fouchardiere A, Vandenesch F, Berger F. Borrelia-associated primary cutaneous MALT lymphoma in a nonendemic region. Am J Surg Pathol 2003; 27:702–703.
Ponzoni M, Ferreri AJ, Mappa S, et al. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. Oncologist 2011; 16:1582–1588.
Travaglino A, Varricchio S, Pace M, et al. Borrelia burgdorferi in primary cutaneous lymphomas: a systematic review and meta-analysis. J Dtsch Dermatol Ges 2020; 18:1379–1384.
Ferreri AJ, Govi S, Ponzoni M. Marginal zone lymphomas and infectious agents. Semin Cancer Biol 2013; 23:431–440.
Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood 2013; 122:1350–1357.
Zucca E, Bertoni F, Vannata B, Cavalli F. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res 2014; 20:5207–5216.
Dasti JI, Tareen AM, Lugert R, et al. Campylobacter jejuni: A brief overview on pathogenicity-associated factors and disease-mediating mechanisms. Int J Med Microbiol 2010; 300:205–211.
Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med 2004; 350:213–215.
Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005; 105:2274–2280.
Cook JR, Harris NL, Isaacson PI, Jaffe ES. Heavy chain diseases. In: Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, A., Stein, H., et, al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition). Lyon: IARC Press; 2017. p. 237-40.
Cook JR, Isaacson PG, Chott A. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition). Lyon: IARC; 2017. 259–262.
Mesnard B, De Vroey B, Maunoury V, Lecuit M. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. Dig Liver Dis 2012; 44:799–800.
Carrillo J, Restrepo CS, Rosado de Christenson M, et al. Lymphoproliferative lung disorders: a radiologic-pathologic overview. Part I: reactive disorders. Semin Ultrasound CT MR 2013; 34:525–534.
Aoyama S, Masaki A, Sakamoto Y, et al. <i>Achromobacter</i> infection is rare in japanese patients with pulmonary b-cell lymphoma. Int Med 2018; 57:789–794.
Kluin PM, Langerak AW, Beverdam-Vincent J, et al. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: a Haemophilus influenzae-driven immune disorder? J Pathol 2015; 236:302–314.
Raoult D, Marrie T, Mege J. Natural history and pathophysiology of Q fever. Lancet Infect Dis 2005; 5:219–226.
Melenotte C, Million M, Audoly G, et al. B-cell non-Hodgkin lymphoma linked to Coxiella burnetii. Blood 2016; 127:113–121.
van Roeden SE, van Houwelingen F, Donkers CMJ, et al. Exposure to Coxiella burnetii and risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the Netherlands. Lancet Haematol 2018; 5:e211–e219.
Bates I, Bedu-Addo G, Rutherford TR, Bevan DH. Circulating villous lymphocytes--a link between hyperreactive malarial splenomegaly and splenic lymphoma. Trans R Soc Trop Med Hyg 1997; 91:171–174.
Jimmy EO, Bedu-Addo G, Bates I, et al. Immunoglobulin gene polymerase chain reaction to distinguish hyperreactive malarial splenomegaly from ’African’ chronic lymphocytic leukaemia and splenic lymphoma. Trans R Soc Trop Med Hyg 1996; 90:37–39.
Bates I, Bedu-Addo G. Chronic malaria and splenic lymphoma: clues to understanding lymphoma evolution. Leukemia 1997; 11:2162–2167.
Kho S, Qotrunnada L, Leonardo L, et al. Hidden biomass of intact malaria parasites in the human spleen. N Engl J Med 2021; 384:2067–2069.
Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018; 378:1085–1095.
Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009; 20:1086–1093.
Ono S, Kato M, Takagi K, et al. Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. J Gastroenterol Hepatol 2010; 25:804–809.
Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori : a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61:507–513.
Strati P, Lee ST, Teegavarupu P, et al. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol 2019; 94:E150–E153.
Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118:821–828.
Okiyama Y, Matsuzawa K, Hidaka E, et al. Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. Pathol Int 2005; 55:398–404.
Takigawa H, Yuge R, Masaki S, et al. Involvement of non-Helicobacter pylori helicobacter infections in Helicobacter pylori-negative gastric MALT lymphoma pathogenesis and efficacy of eradication therapy. Gastric Cancer 2021; 24:937–945.
Kütting B, Bonsmann G, Metze D, et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997; 36 (2 Pt 2):311–314.
Fühler M, Ottmann KW, Tronnier M. [Cutaneous marginal zone lymphoma (SALT) and infection with Borrelia burgdorferi]. Hautarzt 2010; 61:145–147.
Monari P, Farisoglio C, Calzavara Pinton PG. Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report. Dermatology 2007; 215:229–232.
Aberer E, Fingerle V, Wutte N, et al. Within European margins. Lancet 2011; 377:178.
Akbulut H, Soykan I, Yakaryilmaz F, et al. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease. Cancer 1997; 80:8–14.
Evangelista-Leite D, Affonso Madaloso B, Shouta Yamashita B, et al. Treating chronic diarrhea: a systematic review on Immunoproliferative Small Intestinal Disease (IPSID). PLoS One 2021; 16:e0253695.